CDK4 and neoplasm: It proposed for the first time that CDK4/6 inhibitors exhibit a “duality” in activating or inhibiting anti-tumor immunity when interfering with the interferon signaling pathway, inducing cellular senescence, and certain specific immune cell subsets.